Medical Information
United States
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

I am a U.S. Healthcare ProfessionalYes, I am a U.S. Healthcare Professional
SelectI am a U.S. Healthcare ProfessionalYes, I am a U.S. Healthcare Professional
I am a U.S. Patient / CaregiverNo, go back to the patient portal
SelectI am a U.S. Patient / CaregiverNo, go back to the patient portal
Non-US residents click here.

metoprolol tartrate injection, USP - CARPUJECT Highlights

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use METOPROLOL TARTRATE INJECTION safely and effectively. See full prescribing information for METOPROLOL TARTRATE INJECTION.

METOPROLOL TARTRATE Injection, for intravenous use
Initial U.S. Approval: 1978

INDICATIONS AND USAGE

Metoprolol tartrate is a beta-adrenergic receptor inhibitor indicated for the treatment of definite or suspected acute myocardial infarction in hemodynamically stable patients to reduce cardiovascular mortality when used in conjunction with oral metoprolol maintenance therapy. (1)

DOSAGE AND ADMINISTRATION

  • Initiate therapy in a coronary care or similar unit immediately after the patients hemodynamic condition has stabilized. (2)
  • Begin treatment with an intravenous administration of three bolus injections of 5 mg each, at approximately 2-minute intervals. Monitor blood pressure, heart rate and electrocardiogram. (2)
  • Following administration of Metoprolol tartrate injection, transition the patient to an oral formulation of metoprolol. (2)

DOSAGE FORMS AND STRENGTHS

Injection: 5 mg metoprolol tartrate supplied in 5 mL ampules. (3)

CONTRAINDICATIONS

  • Known hypersensitivity to product components. (4)
  • Severe bradycardia, greater than first degree heart block, or sick sinus syndrome without a pacemaker. (4)
  • Cardiogenic shock or decompensated heart failure. (4)

WARNINGS AND PRECAUTIONS

  • Worsening cardiac failure may occur. (5.2)
  • Bronchospastic Disease: Avoid beta-blockers. (5.3)
  • Pheochromocytoma: First initiate therapy with an alpha blocker. (5.4)
  • May aggravate symptoms of arterial insufficiency. (5.5)

ADVERSE REACTIONS

  • Most common adverse reactions: tiredness, dizziness, shortness of breath, bradycardia, hypotension, pruritus (6.1).

To report SUSPECTED ADVERSE REACTIONS, contact Hospira, Inc. at 1-800-441-4100, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

  • Catecholamine depleting drugs may have an additive effect when given with beta-blocking agents. (7.1)
  • Patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction. (7.2)
  • CYP2D6 Inhibitors are likely to increase metoprolol concentration. (7.3)
  • Concomitant use of glycosides, clonidine, and diltiazem and verapamil with beta-blockers can increase the risk of bradycardia. (7.4)
  • Beta-blockers including metoprolol, may exacerbate the rebound hypertension that can follow the withdrawal of clonidine. (7.4)

USE IN SPECIFIC POPULATIONS

  • Hepatic Impairment: Consider initiating metoprolol tartrate therapy at low doses while monitoring closely for adverse events. (8.6)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 4/2021

Show All Hide All
Show All Hide All
Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.
MI Digital Assistant

Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.

Call 800-438-1985*

*Contact Medical Information.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event
Pfizer Safety

To report an adverse event related to Pfizer-BioNTech COVID-19 Vaccine (also known as COMIRNATY®, COVID-19 mRNA, Vaccine BNT162b2 or BNT162) or Pfizer COVID-19 Treatment (also known as PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets)), and you are not part of a clinical trial* for this product, click the link below to submit your information:

Pfizer Safety Reporting Site

*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.

If you cannot use the above website or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at
(800) 438-1985.
FDA Medwatch
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatchor by calling
(800)-332-1088.